Jake joined NEA in 2006 as a Partner.  He focuses on later-stage specialty pharmaceuticals, biotechnology and medical device investments and manages a number of NEA's public investments in healthcare.  Jake is a Director of Dermira (Nasdaq: DERM), Hyperion Therapeutics (Nasdaq: HPTX), Trevena, Inc. (Nasdaq: TRVN), and TriVascular (Nasdaq:TRIV).  He previously was a Director of Aciex Therapeutics (sold to Nicox SA) and Transcept Pharmaceuticals (merged with Paratek Pharmaceuticals).  Jake worked at MPM Capital as a Partner with the MPM BioEquities Fund, where he specialized in public, PIPE and mezzanine-stage life sciences investing. Previously, he was a healthcare research analyst and portfolio manager at Franklin Templeton Investments. Jake was also an investment banker with Alex. Brown & Sons. He received an MBA from the Stanford Graduate School of Business and an AB in Economics from Dartmouth College. Jake holds the Chartered Financial Analyst designation, and is a member of the CFA Society of San Francisco.

Companies